TETRAPHARM appoints Rolf Sass Sørensen as CEO
Biopharmaceutical company TETRAPHARM has appointed Rolf Sass Sørensen as its new Chief Executive Officer, succeeding co-founder Martin Rose.
COPENHAGEN, Denmark – TETRAPHARM has appointed Rolf Sass Sørensen as its new Chief Executive Officer, effective October 6, 2026. He succeeds co-founder Martin Rose, who established the company with Jesper Breum in 2018.
The leadership change occurs as TETRAPHARM advances its novel drug molecules and proprietary drug delivery technologies, alongside its contract development and manufacturing (CDMO) services for pharmaceutical partners. Sørensen will lead the company's continued development in collaboration with the Board of Directors and the organization.
Rolf Sass Sørensen brings over 30 years of experience, including senior roles in investor relations and corporate communications. Previously Vice President Investor Relations & Communications at Bavarian Nordic, he possesses extensive knowledge of the life sciences sector and the dynamics between biotechnology firms and capital markets.
Founders Martin Rose and Jesper Breum are transitioning from their operational roles to pursue new biotech ventures, while remaining shareholders in TETRAPHARM. Sørensen stated his responsibility is to translate the company's potential into clear priorities and measurable progress, working with the team.